Shares of Tarsus Pharmaceuticals (NASDAQ: TARS) rallied 9.1% on Friday, closing at $90.78, after the company finalized its acquisition of Alkeus Pharmaceuticals. The stock's surge reflects the increased value of the equity portion of the deal, which is now worth approximately $266.2 million based on the closing price. This brings the total upfront package to about $536.2 million, up from the $450 million headline figure announced when the deal was signed.
The transaction, initially valued at $270 million in cash and $180 million in Tarsus stock, was priced at $61.38 per share at signing. With Friday's close at $90.78, the 2.93 million shares issued to Alkeus holders have appreciated by roughly $86.2 million. This increase underscores the economic benefit to Alkeus shareholders, who participate in Tarsus's recent rally, while existing Tarsus shareholders absorb the additional dilution.
Market Reaction and Trading Details
Tarsus shares traded between $81.07 and $91.53 on Friday, finishing near the session high on volume of 1.60 million shares. The stock has climbed for three consecutive sessions, from $74.24 on August 31 to $90.78 on September 4. This rally added an estimated $371.5 million to the company's pro forma equity value.
The acquisition shares represent approximately 6.0% of the estimated 49.0 million pro forma share equivalents. This dilution is a key consideration for investors, as future regulatory milestones may be paid in stock, potentially increasing the share count further.
Deal Structure and Future Milestones
Beyond the upfront package, the deal includes up to $350 million in regulatory and commercial milestones, as well as tiered royalties in the low-to-mid single digits on net sales. The $250 million regulatory milestone may be settled in cash, stock, or a combination, at Tarsus's option.
Tarsus also raised $125 million in a private placement tied to the transaction. As of June, the company held $449.7 million in cash and marketable securities. After accounting for the two acquisition cash payments and the financing, Tarsus retains roughly $267.2 million in liquidity, before fees and operating expenses.
Clinical Pipeline and XDEMVY Performance
The acquisition brings gildeuretinol, a potential treatment for Stargardt disease, an inherited retinal disorder with no FDA-approved therapy. Tarsus estimates that 86,000 patients in the U.S. have the condition, including about 36,000 diagnosed cases, making it a meaningful orphan drug opportunity.
Earlier studies, TEASE-1 and TEASE-2, showed promising results, but the pivotal NORTHSTAR trial is the key catalyst. The study plans to enroll approximately 230 patients, with topline results expected in the second half of 2029. The primary endpoint measures retinal lesion growth over 24 months, with low-light visual acuity as a key secondary measure.
Meanwhile, Tarsus's commercial product, XDEMVY, continues to perform well. Second-quarter sales rose 69% year-over-year to $173.9 million, and management has guided to full-year sales of $685 million to $705 million. However, spending is also rising, with R&D expenses nearly doubling to $31.0 million and SG&A expenses reaching $150.7 million in the quarter.
Analyst Perspective and Risks
The stock's 48% rise since August 5 cannot be attributed solely to the Alkeus deal; XDEMVY growth and the capital raise also contributed. Friday's move suggests investors are now pricing in the completed acquisition and the potential of the pipeline.
Key risks include the 2029 readout of NORTHSTAR, which may not replicate earlier positive results. A delay would extend spending without potential product revenue. Dilution remains a concern, as regulatory milestones could be paid in shares, and commercial success would trigger additional cash payments and royalties.
Investors now have a clear metric: XDEMVY must support the expanded pipeline without eroding liquidity, and NORTHSTAR must justify an upfront package already exceeding half a billion dollars.
